Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122843 | 0.89 | KRAS (0.51) | GAARBP4MEN1KMT2ASCD | |
| SCHEMBL16117783 | 0.83 | KRAS (0.48) | GAARBP4MEN1KMT2ASCD | |
| SCHEMBL16122844 | 0.83 | KRAS (0.46) | GAAEGFR | |
| SCHEMBL22984916 | 0.82 | CYP11B2 (0.46) | GAAALKSCD | |
| SCHEMBL16117782 | 0.81 | KRAS (0.46) | GAASCDEGFR | |
| SCHEMBL30104233 | 0.81 | KRAS (0.53) | GAAMEN1KMT2ASCDEGFR | |
| SCHEMBL16102800 | 0.81 | KRAS (0.53) | GAAMEN1KMT2ASCDEGFR | |
| SCHEMBL16122269 | 0.81 | GAA (0.47) | GAACD274ALKMEN1KMT2A | |
| SCHEMBL16102324 | 0.80 | GAA (0.44) | GAACD274ALKMEN1KMT2A | |
| SCHEMBL16117727 | 0.79 | KRAS (0.50) | GAAMEN1KMT2ASCDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | GAA 1747/4885PDCD1LG2 2275/4885CD274 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.